Enliven Therapeutics, Inc.
ELVN
$18.73
-$0.08-0.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.52% | 57.93% | 56.54% | 40.72% | 54.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.61% | 31.30% | 44.94% | 68.53% | 91.70% |
| Operating Income | -23.61% | -31.30% | -44.94% | -68.53% | -91.70% |
| Income Before Tax | -18.84% | -24.04% | -37.59% | -60.23% | -82.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.14% | -24.36% | -37.97% | -60.68% | -82.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.14% | -24.36% | -37.97% | -60.68% | -82.08% |
| EBIT | -23.61% | -31.30% | -44.94% | -68.53% | -91.70% |
| EBITDA | -23.69% | -31.39% | -45.08% | -68.77% | -92.03% |
| EPS Basic | -0.19% | 12.85% | 58.72% | 73.81% | 80.42% |
| Normalized Basic EPS | -6.07% | 8.28% | 58.94% | 74.62% | 81.38% |
| EPS Diluted | -0.19% | 12.85% | 58.72% | 73.81% | 80.42% |
| Normalized Diluted EPS | -6.07% | 8.28% | 58.94% | 74.62% | 81.38% |
| Average Basic Shares Outstanding | 18.82% | 32.91% | 72.96% | 161.08% | 487.13% |
| Average Diluted Shares Outstanding | 18.82% | 32.91% | 72.96% | 161.08% | 487.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |